![Stefan Weber](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stefan Weber
Directeur Général chez
NEWRON PHARMACEUTICALS S.P.A.
Profil
Stefan Weber currently works at Newron Pharmaceuticals SpA, as Chief Executive Officer & Director from 2012, Newron Suisse SA, as Chairman & Chief Executive Officer, Hunter-Fleming Ltd., as Director, Newron Sweden AB, as General Manager & Director, and Newron Pharmaceuticals US, Inc., as Director.
Mr. Weber also formerly worked at Girindus AG i.L., as Chief Financial Officer from 2000 to 2001, Biofrontera AG, as Chief Financial Officer from 2001 to 2005, and Nikolaus & Claudius Lohmann, as Head-Finance from 1987 to 1999.
Mr. Weber received his graduate degree from the University of Hagen.
Postes actifs de Stefan Weber
| Sociétés | Poste | Début |
|---|---|---|
| NEWRON PHARMACEUTICALS S.P.A. | Directeur Général | 15/05/2012 |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders | Directeur/Membre du Conseil | - |
Newron Pharmaceuticals US, Inc.
 Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease. | Directeur/Membre du Conseil | - |
Newron Suisse SA | Directeur Général | - |
Hunter-Fleming Ltd.
 Hunter-Fleming Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Directeur/Membre du Conseil | - |
Anciens postes connus de Stefan Weber
| Sociétés | Poste | Fin |
|---|---|---|
| BIOFRONTERA AG | Directeur Financier/CFO | 01/01/2005 |
| GIRINDUS AG IL | Directeur Financier/CFO | 01/01/2001 |
Nikolaus & Claudius Lohmann | Directeur Financier/CFO | 01/01/1999 |
Formation de Stefan Weber
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
20
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Girindus AG i.L.
 Girindus AG i.L. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical products and chemical intermediate products | Health Technology |
Hunter-Fleming Ltd.
Hunter-Fleming Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Biofrontera AG
 Biofrontera AG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops and distributes dermatological products | Health Technology |
Newron Pharmaceuticals SpA
 Newron Pharmaceuticals SpA Pharmaceuticals: MajorHealth Technology Develops and sells novel therapies central & peripheral nervous system | Health Technology |
Newron Sweden AB
Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders | Health Technology |
University of Hagen
 University of Hagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Newron Suisse SA | |
Newron Pharmaceuticals US, Inc.
Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease. | Commercial Services |
Nikolaus & Claudius Lohmann |
